Abstract PDF Similar Articles Mail to Author

¹Third Military Medical University, Institute of Surgery Research, DaPing Hospital, Department of Neurosurgery, Chongqing, China
²Third Military Medical University, Institute of Surgery Research, DaPing Hospital, Department of Geriatrics, Chongqing, China DOI : 10.5137/1019-5149.JTN.8878-13.1 The aim of this study was to a conduct a systematic review of carmustine wafers (Gliadel wafers) for the treatment of glioblastoma multiforme (GBM) to assess the survival benefit and safety of this therapy. The inclusion criteria were 1) prospective or retrospective clinical trial; 2) patients who had undergone resection for primary GBM or first recurrence of GBM with or without carmustine wafer implantation; 3) patients with malignant gliomas that included GBM; 4) outcomes including survival analysis of the GBM population. Six trials met the inclusion criteria; four were randomized, controlled trials and two were retrospective. The trials varied with regard to the type of patients and interventions. In three of the trials, patients with GBM who received carmustine wafers had significantly longer median survival than patients who did not receive wafers. Implantation of carmustine wafers did not significantly improve progression-free survival. Carmustine wafers did not increase adverse effects. This systematic review suggests that carmustine wafers have demonstrated promise as an effective and tolerable treatment in comparison to other treatment strategies in patients with GBM. Keywords : Glioblastoma multiforme, Carmustine wafers, Gliadel wafers, BCNU wafers